Literature DB >> 24212098

The two faces of heterologous immunity: protection or immunopathology.

Shalini Sharma1, Paul G Thomas.   

Abstract

Immunity to previously encountered viruses can alter responses to unrelated pathogens. This phenomenon, which is known as heterologous immunity, has been well established in animal model systems. Heterologous immunity appears to be relatively common and may be beneficial by boosting protective responses. However, heterologous reactivity can also result in severe immunopathology. The key features that define heterologous immune modulation include alterations in the CD4(+) and CD8(+) T cell compartments and changes in viral dynamics and disease progression. In this review, we discuss recent advances and the current understanding of antiviral immunity in heterologous infections. The difficulties of studying these complex heterologous infections in humans are discussed, with special reference to the variations in HLA haplotypes and uncertainties about individuals' infection history. Despite these limitations, epidemiological analyses in humans and the data from mouse models of coinfection can be applied toward advancing the design of therapeutics and vaccination strategies.

Entities:  

Keywords:  T cell repertoire; attrition; bystander activation; cross-reactivity; heterologous viral infections; immunity; immunodominance

Mesh:

Year:  2013        PMID: 24212098      PMCID: PMC3923083          DOI: 10.1189/jlb.0713386

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  107 in total

1.  T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens.

Authors:  Michael A Brehm; Amelia K Pinto; Keith A Daniels; Jonathan P Schneck; Raymond M Welsh; Liisa K Selin
Journal:  Nat Immunol       Date:  2002-06-03       Impact factor: 25.606

2.  Dengue immune response: low affinity, high febrility.

Authors:  Raymond M Welsh; Alan L Rothman
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

Review 3.  Helping the CD8(+) T-cell response.

Authors:  Michael J Bevan
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

Review 4.  The expanding realm of heterologous immunity: friend or foe?

Authors:  Kathleen R Page; Alan L Scott; Yukari C Manabe
Journal:  Cell Microbiol       Date:  2006-02       Impact factor: 3.715

5.  Differential usage of cellular niches by cytomegalovirus versus EBV- and influenza virus-specific CD8+ T cells.

Authors:  Ester M M van Leeuwen; Jasper J Koning; Ester B M Remmerswaal; Debbie van Baarle; René A W van Lier; Ineke J M ten Berge
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

Review 6.  No one is naive: the significance of heterologous T-cell immunity.

Authors:  Raymond M Welsh; Liisa K Selin
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

7.  HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor.

Authors:  Tao Dong; Guillaume Stewart-Jones; Nan Chen; Philippa Easterbrook; Xiaoning Xu; Laura Papagno; Victor Appay; Michael Weekes; Chris Conlon; Celsa Spina; Susan Little; Gavin Screaton; Anton van der Merwe; Douglas D Richman; Andrew J McMichael; E Yvonne Jones; Sarah L Rowland-Jones
Journal:  J Exp Med       Date:  2004-12-13       Impact factor: 14.307

8.  Private specificities of CD8 T cell responses control patterns of heterologous immunity.

Authors:  Sung-Kwon Kim; Markus Cornberg; Xiaoting Z Wang; Hong D Chen; Liisa K Selin; Raymond M Welsh
Journal:  J Exp Med       Date:  2005-02-14       Impact factor: 14.307

9.  Viral infection of transgenic mice expressing a viral protein in oligodendrocytes leads to chronic central nervous system autoimmune disease.

Authors:  C F Evans; M S Horwitz; M V Hobbs; M B Oldstone
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

10.  Cross-reactivity between HLA-A2-restricted FLU-M1:58-66 and HIV p17 GAG:77-85 epitopes in HIV-infected and uninfected individuals.

Authors:  Paula M Acierno; Danforth A Newton; Edwin A Brown; Lou Anne Maes; John E Baatz; Sebastiano Gattoni-Celli
Journal:  J Transl Med       Date:  2003-08-14       Impact factor: 5.531

View more
  19 in total

Review 1.  Virological and Immunological Outcomes of Coinfections.

Authors:  Naveen Kumar; Shalini Sharma; Sanjay Barua; Bhupendra N Tripathi; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2018-07-05       Impact factor: 26.132

Review 2.  Ecological and evolutionary dynamics of multi-strain RNA viruses.

Authors:  Dennis N Makau; Samantha Lycett; Matthew Michalska-Smith; Igor A D Paploski; Maxim C-J Cheeran; Meggan E Craft; Rowland R Kao; Declan C Schroeder; Andrea Doeschl-Wilson; Kimberly VanderWaal
Journal:  Nat Ecol Evol       Date:  2022-09-22       Impact factor: 19.100

3.  Transcriptomics of Acute DENV-Specific CD8+ T Cells Does Not Support Qualitative Differences as Drivers of Disease Severity.

Authors:  Alba Grifoni; Hannah Voic; Esther Dawen Yu; Jose Mateus; Kai Mei Yan Fung; Alice Wang; Grégory Seumois; Aruna D De Silva; Rashika Tennekon; Sunil Premawansa; Gayani Premawansa; Rashmi Tippalagama; Ananda Wijewickrama; Ashu Chawla; Jason Greenbaum; Bjoern Peters; Vijayanand Pandurangan; Daniela Weiskopf; Alessandro Sette
Journal:  Vaccines (Basel)       Date:  2022-04-14

Review 4.  An Update on Host-Pathogen Interplay and Modulation of Immune Responses during Orientia tsutsugamushi Infection.

Authors:  Fabián E Díaz; Katia Abarca; Alexis M Kalergis
Journal:  Clin Microbiol Rev       Date:  2018-01-31       Impact factor: 26.132

Review 5.  Manipulating the TCR signaling network for cellular immunotherapy: Challenges & opportunities.

Authors:  Courtney A Matson; Nevil J Singh
Journal:  Mol Immunol       Date:  2020-05-15       Impact factor: 4.174

Review 6.  Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines.

Authors:  Saranya Sridhar
Journal:  Front Immunol       Date:  2016-05-19       Impact factor: 7.561

7.  Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?

Authors:  David K Meyerholz; Stanley Perlman
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

8.  Complexities in Isolation and Purification of Multiple Viruses from Mixed Viral Infections: Viral Interference, Persistence and Exclusion.

Authors:  Naveen Kumar; Sanjay Barua; Thachamvally Riyesh; Kundan K Chaubey; Krishan Dutt Rawat; Nitin Khandelwal; Anil K Mishra; Nitika Sharma; Surender S Chandel; Shalini Sharma; Manoj K Singh; Dinesh K Sharma; Shoor V Singh; Bhupendra N Tripathi
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

9.  Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans.

Authors:  Alba Grifoni; John Pham; John Sidney; Patrick H O'Rourke; Sinu Paul; Bjoern Peters; Sheridan R Martini; Aruna D de Silva; Michael J Ricciardi; Diogo M Magnani; Cassia G T Silveira; Alvino Maestri; Priscilla R Costa; Luzia Maria de-Oliveira-Pinto; Elzinandes Leal de Azeredo; Paulo Vieira Damasco; Elizabeth Phillips; Simon Mallal; Aravinda M de Silva; Matthew Collins; Anna Durbin; Sean A Diehl; Cristhiam Cerpas; Angel Balmaseda; Guillermina Kuan; Josefina Coloma; Eva Harris; James E Crowe; Mars Stone; Phillip J Norris; Michael Busch; Hector Vivanco-Cid; Josephine Cox; Barney S Graham; Julie E Ledgerwood; Lance Turtle; Tom Solomon; Esper G Kallas; David I Watkins; Daniela Weiskopf; Alessandro Sette
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

10.  Co-infections determine patterns of mortality in a population exposed to parasite infection.

Authors:  Mark E J Woolhouse; Samuel M Thumbi; Amy Jennings; Margo Chase-Topping; Rebecca Callaby; Henry Kiara; Marinda C Oosthuizen; Mary N Mbole-Kariuki; Ilana Conradie; Ian G Handel; E Jane Poole; Evalyne Njiiri; Nicola E Collins; Gemma Murray; Miika Tapio; Olga Tosas Auguet; Willie Weir; W Ivan Morrison; Loeske E B Kruuk; B Mark de C Bronsvoort; Olivier Hanotte; Koos Coetzer; Philip G Toye
Journal:  Sci Adv       Date:  2015-03-20       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.